Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006).

To see the English language version of this discussion, click here.

Solid Tumors

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).

Breast Cancer

Paul E. Goss, MD, PhD, on Postmenopausal Early-Stage Breast Cancer: Extending Letrozole Treatment

Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).

Leukemia

Lymphoma

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).

Palliative Care

Ronald C. Chen, MD, MPH, on End-of-Life Care: Impact of the Choosing Wisely Campaign

Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, discusses the substantial overuse of aggressive medical care for younger patients at the end of life, despite ASCO recommendations (Abstract LBA10033).

Feb

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

Paul E. Goss, MD, PhD, on Postmenopausal Early-Stage Breast Cancer: Extending Letrozole Treatment

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Ronald C. Chen, MD, MPH, on End-of-Life Care: Impact of the Choosing Wisely Campaign

Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology

Does Diabetes Increase Pancreatic Cystic Neoplasm Risk

Topline PFS Results From BREAKWATER in mCRC Newly Announced

Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer

Pleurectomy Decortication Safe in Select Patients With Pleural Mesothelioma